| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/26/2013 | US8404660 Method of obtaining of 4-N-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-N-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition |
| 03/26/2013 | US8404657 Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx) |
| 03/26/2013 | US8404655 Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity |
| 03/26/2013 | US8404651 Compositions and methods for treating viral infections |
| 03/26/2013 | US8404650 Methods of treating cancer with doxazolidine and prodrugs thereof |
| 03/26/2013 | US8404649 Isoxazoline oximes as antiparasitic agents |
| 03/26/2013 | US8404641 Macrocyclic lactone compounds and methods for their use |
| 03/26/2013 | US8404635 Orally administered peptides synergize statin activity |
| 03/26/2013 | US8404633 CD5 pharmaceutical compositions for the treatment of infectious and inflammatory processes of fungal origin |
| 03/26/2013 | US8404300 Drug releasing coatings for medical devices |
| 03/26/2013 | US8404277 Matrix-type transdermal drug delivery system and preparation method thereof |
| 03/26/2013 | US8404276 Pulmonary delivery for levodopa |
| 03/26/2013 | US8404274 Aseptic combination preparation |
| 03/26/2013 | US8404267 Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer |
| 03/26/2013 | US8404265 Contact lenses for extended release of bioactive agents containing diffusion attenuators |
| 03/26/2013 | US8404226 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 03/26/2013 | US8404224 Cationic betaine precursors to zwitterionic betaines having controlled biological properties |
| 03/26/2013 | US8404223 Polymer |
| 03/26/2013 | US8404222 Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| 03/26/2013 | US8404220 Production of adapalene gels |
| 03/26/2013 | US8404213 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| 03/26/2013 | US8403910 Drug releasing coatings for medical devices |
| 03/26/2013 | CA2791142A1 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| 03/26/2013 | CA2724151C Novel derivatives of azabicyclo[3.2.0]hept-3-yl, their preparation process and the pharmaceutical compounds that contain them |
| 03/26/2013 | CA2712619C Dihydropyridine calcium antagonist compounds, preparation methods and medical uses thereof |
| 03/26/2013 | CA2670284C Synthesis of compounds useful as modulators of amyloid-beta production |
| 03/26/2013 | CA2649895C Stable hydroalcoholic oral spray formulations and methods |
| 03/26/2013 | CA2631737C Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
| 03/26/2013 | CA2612865C Thiazolopyrimidines for the therapy of hyperalgesic pain conditions |
| 03/26/2013 | CA2583845C 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt |
| 03/26/2013 | CA2565295C Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 03/26/2013 | CA2555328C Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis |
| 03/26/2013 | CA2551602C Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| 03/26/2013 | CA2545752C Treatment and prevention of liver disease associated with parenteral nutrition (pn) |
| 03/26/2013 | CA2537820C Process for preparing water-soluble medicaments comprising complexation of forskolin in cyclodextrins |
| 03/26/2013 | CA2532626C Particles containing an active agent in the form of a co-precipitate |
| 03/26/2013 | CA2531485C Malonamide derivatives |
| 03/26/2013 | CA2513773C Clindamycin phosphate foam |
| 03/26/2013 | CA2495938C A wide spectrum disinfectant |
| 03/26/2013 | CA2474424C Salts of valsartan |
| 03/26/2013 | CA2457925C Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 03/26/2013 | CA2424207C Stem cell differentiation-inducing promoter |
| 03/26/2013 | CA2395197C Acyl pseudodipeptides which carry a functionalised auxiliary arm |
| 03/26/2013 | CA2262459C Gene involved in cadasil, method of diagnosis and therapeutic application |
| 03/21/2013 | WO2013040577A1 Aptamers resistant to nucleocapsid degradation |
| 03/21/2013 | WO2013040568A1 Methods for treating hcv |
| 03/21/2013 | WO2013040556A1 Compositions of jasmonate compounds and methods of use |
| 03/21/2013 | WO2013040552A2 Methods of promoting immune tolerance |
| 03/21/2013 | WO2013040535A2 Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same |
| 03/21/2013 | WO2013040528A1 Antimicrobial compounds |
| 03/21/2013 | WO2013040527A1 Antimicrobial compounds |
| 03/21/2013 | WO2013040520A1 Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury |
| 03/21/2013 | WO2013040515A1 Certain chemical entities, compositions, and methods |
| 03/21/2013 | WO2013040507A1 Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy |
| 03/21/2013 | WO2013040492A2 Methods for treating hcv |
| 03/21/2013 | WO2013040471A2 Noribogaine salt ansolvates |
| 03/21/2013 | WO2013040447A2 Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis |
| 03/21/2013 | WO2013040445A1 Arrays for cell-based screening and uses thereof |
| 03/21/2013 | WO2013040442A1 Phased dosing of clopidogrel |
| 03/21/2013 | WO2013040441A1 Plant steroids and uses thereof |
| 03/21/2013 | WO2013040439A2 CBP and p300-MEDIATED TRANSCRIPTION MODULATORS AND RELATED METHODS |
| 03/21/2013 | WO2013040436A2 Esx-mediated transcription modulators and related methods |
| 03/21/2013 | WO2013040412A2 Methods for inhibiting bacteria growth |
| 03/21/2013 | WO2013040337A1 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer |
| 03/21/2013 | WO2013040295A2 Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation |
| 03/21/2013 | WO2013040286A2 Pharmaceutical compositions |
| 03/21/2013 | WO2013040269A1 Products for healing of tissue wounds |
| 03/21/2013 | WO2013040265A1 Compositions for treating bone diseases and broken bones |
| 03/21/2013 | WO2013040226A1 Method for enhancing crop yields by application of trehalose |
| 03/21/2013 | WO2013040222A1 Cluster boron compounds and uses thereof |
| 03/21/2013 | WO2013040215A1 Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| 03/21/2013 | WO2013040183A1 Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof |
| 03/21/2013 | WO2013040164A1 Compositions and methods for treating metabolic disorders |
| 03/21/2013 | WO2013040153A1 TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY |
| 03/21/2013 | WO2013040120A1 Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
| 03/21/2013 | WO2013040068A2 Process for preparing synthetic prostacyclins |
| 03/21/2013 | WO2013040059A1 Novel imidazole amines as modulators of kinase activity |
| 03/21/2013 | WO2013040044A1 Aminopyrimidine derivatives for use as modulators of kinase activity |
| 03/21/2013 | WO2013040027A1 Reprogramming immune environment in breast cancer via dendritic cells |
| 03/21/2013 | WO2013039994A2 Apparatus, composition, and related methods for transdermal delivery of active ingredients |
| 03/21/2013 | WO2013039956A2 Compositions and methods for treating mood disorders |
| 03/21/2013 | WO2013039948A1 Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof |
| 03/21/2013 | WO2013039947A1 Polymorphs of n-((s)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1r,2r)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide |
| 03/21/2013 | WO2013039880A1 Biomarkers and therapeutic targets of hepatocellular cancer |
| 03/21/2013 | WO2013039855A1 Compounds and pharmaceutical compositions for the treatment of viral infections |
| 03/21/2013 | WO2013039851A1 Optical agents for imaging and visualization of matrix metalloproteinase enzymes |
| 03/21/2013 | WO2013039802A1 Inhibitors of the renal outer medullary potassium channel |
| 03/21/2013 | WO2013039785A2 Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 03/21/2013 | WO2013039764A1 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
| 03/21/2013 | WO2013039706A1 Drug delivery systems and applications |
| 03/21/2013 | WO2013039597A2 Method for enhancing the growth and fullness of hair |
| 03/21/2013 | WO2013039488A1 Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| 03/21/2013 | WO2013039424A1 Method for preparing an adsorbed drone brood and the composition thereof |
| 03/21/2013 | WO2013039380A1 Sterile alginate-based aqueous composition for medical use and process for the preparation thereof |
| 03/21/2013 | WO2013039367A1 Preparation that effectively reduces high glutamate level in blood |
| 03/21/2013 | WO2013039350A2 Skin composition for external use containing ceramides |
| 03/21/2013 | WO2013039210A1 Gip elevation inhibitor |
| 03/21/2013 | WO2013039202A1 Novel acrylic acid derivative |
| 03/21/2013 | WO2013039197A1 IκB KINASE α ACTIVATION INHIBITOR |
| 03/21/2013 | WO2013039187A1 Guanidinobenzoic acid compound |